

ALDER BIOPHARMACEUTICALS INC

Form 4

September 02, 2015

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
SRB Associates IX L.P.

2. Issuer Name **and** Ticker or Trading
Symbol
ALDER BIOPHARMACEUTICALS
INC [ALDR]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
13355 NOEL ROAD, SUITE 1350

3. Date of Earliest Transaction
(Month/Day/Year)
08/31/2015

____ Director ____ 10% Owner
____ Officer (give title ____X____ Other (specify
below) below)
Affiliate

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
X Form filed by More than One Reporting
Person

DALLAS, TX 75240

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/31/2015		S	16,218 (1)	\$ 38.7508 88 (2)	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form
displays a currently valid OMB control
number.**

SEC 1474
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Owned Following Reported Transaction (Instr. 6)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SRB Associates IX L.P. 13355 NOEL ROAD SUITE 1350 DALLAS, TX 75240				Affiliate
Sevin Rosen Fund IX L.P. 13355 NOEL ROAD, SUITE 1350 DALLAS, TX 75240				Affiliate
Sevin Rosen IX Affiliates Fund L.P. 13355 NOEL ROAD, SUITE 1350 DALLAS, TX 75240				Affiliate

Signatures

John V. Jagers, Attorney-In-Fact For SRB Associates IX L.P.	09/02/2015
__Signature of Reporting Person	Date
John V. Jagers, Attorney-In-Fact For Sevin Rosen Fund IX L.P.	09/02/2015
__Signature of Reporting Person	Date
John V. Jagers, Attorney-In-Fact For Sevin Rosen IX Affiliates Fund L.P.	09/02/2015
__Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents 15,877 Common Shares sold directly by Sevin Rosen Fund IX L.P. and 341 Common Shares sold directly by Sevin Rosen IX Affiliates Fund L.P. pursuant to Rule 144 under the Securities Act of 1933, as amended.
- (2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at pricing ranging from \$38.61 to \$38.92 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.